Biomarin Pharmaceut (BMRN) 81.10 $BMRN 4 Stocks That

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 9:12 AM

Biomarin Pharmaceut (BMRN) 81.10 $BMRN

4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 246.13 (-4.33), BMRN: 81.10 (-1.84), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), IBB: 267.60 (-5.98), REGN: 372.03 (-9.05)

Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 81.10 (-1.84), ALXN: 135.61 (-2.63), AEGR: 1.37 (-0.13), ACOR: 27.07 (-0.45)

BioMarin Pharmaceutical Falls 4.20% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 07, 3:13PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $85.23 to a high of $89.30. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $87.17 on volume of 597,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMRN: 81.10 (-1.84)

Sarepta Asked to Provide Dystrophin Data on Eteplirsen
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:23AM CDT
Sarepta (SRPT) announced that the FDA has requested for dystrophin data from biopsies on eteplirsen, as part of the ongoing evaluation of the NDA.
BMRN: 81.10 (-1.84), SRPT: 19.95 (-1.04), PFE: 35.29 (-0.02), BMY: 72.65 (-0.08)

BioMarin Withdraws Kyndrisa Marketing Application in EU
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 6:49AM CDT
BioMarin (BMRN) has withdrawn its regulatory application for Kyndrisa from the EU, following discussions with the EMA's CHMP.
BMRN: 81.10 (-1.84), ANIP: 52.05 (-1.64), SRPT: 19.95 (-1.04), BMY: 72.65 (-0.08)

BioMarin Pharmaceutical Rises 1.39% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 3:06PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $89.35 to a high of $91.25. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $89.85 on volume of 558,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 81.10 (-1.84)

BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa(TM) (drisapersen) in Europe
GlobeNewswire - Tue May 31, 3:05PM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has withdrawn its Kyndrisa(TM) (drisapersen) Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) following discussions at the May 2016 Committee for Medicinal Products for Human Use (CHMP) meeting. Those discussions clearly indicated that the CHMP intended to issue a negative opinion. Kyndrisa is an experimental drug for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
BMRN: 81.10 (-1.84)

Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 81.10 (-1.84), PFE: 35.29 (-0.02), BMY: 72.65 (-0.08)

Look for Shares of BioMarin Pharmaceutical to Potentially Pullback after Yesterday's 2.74% Rise
Comtex SmarTrend(R) - Wed May 18, 3:27PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $83.21 to a high of $87.51. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $87.50 on volume of 599,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 81.10 (-1.84)

Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 14.80 (-0.44), BMRN: 81.10 (-1.84), PFE: 35.29 (-0.02)

AbSci Appoints Daniel Gold, Ph.D. to Board of Directors
PR Newswire - Mon May 16, 7:00AM CDT
AbSci announced today the appointment of Daniel Gold, Ph.D. to AbSci's Board of Directors. Dr. Gold has served in senior management roles at several leading biotechnology companies and currently serves as Vice President of Process Sciences at BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN).
BMRN: 81.10 (-1.84)

BioMarin to Attend Upcoming Investor Conferences
GlobeNewswire - Wed May 04, 7:30AM CDT
- Bank of America Merrill Lynch 2016 Health Care Conference on May 11 in Las Vegas
BMRN: 81.10 (-1.84)

BioMarin Announces EMA Grants Accelerated Assessment for Cerliponase Alfa, Experimental Treatment for a Form of Batten Disease
GlobeNewswire - Tue May 03, 7:25AM CDT
EU and U.S. Marketing Application Submissions Planned for Mid-Year 2016
BMRN: 81.10 (-1.84)

BioMarin Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 3:02PM CDT
-First Quarter 2016 Total BioMarin Revenue Increases 16.7% Y/Y to $236.7 million
BMRN: 81.10 (-1.84)

Why Sarepta Therapeutics Inc. Is Up Big Today
Brian Feroldi, The Motley Fool - Motley Fool - Thu Apr 28, 1:36PM CDT
IMAGE SOURCE: TBIT ON PIXABAY. What: Shares of biotech stock Sarepta Therapeutics are surging more than 26% higher as of 1:15 p.m. ET after a bullish article by TheStreet.com's Adam Feurstein suggests that the company's Duchenne muscular...
BMRN: 81.10 (-1.84), SRPT: 19.95 (-1.04)

Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 4.00 (-0.19), BIIB: 246.13 (-4.33), JNJ: 117.01 (+0.01), BMRN: 81.10 (-1.84), SHPG: 177.10 (-6.85), IMGN: 4.96 (-0.11), BXLT: 46.02 (-0.18), KERX: 5.93 (-0.12), NVS: 78.94 (-1.57)

Should You Buy BioMarin Pharmaceutical (BMRN) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 7:57AM CDT
BioMarin Pharmaceutical (BMRN) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory
BMRN: 81.10 (-1.84)

Despite Pleas, FDA Panel Shuns Drug
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 27, 7:21AM CDT
SOURCE: SAREPTA THERAPEUTICS, INC. Mostly positive testimony from 52 patient advocates failed to persuade a key FDA advisory panel to vote in favor of approving Sarepta Therapeutics controversial new therapy for Duchenne's muscular dystrophy...
BMRN: 81.10 (-1.84), SRPT: 19.95 (-1.04)

Alexion (ALXN) Q1 Earnings: What's in Store for the Stock?
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 5:53PM CDT
Alexion (ALXN) will report first-quarter 2016 earnings on Apr 28 before market opens.
BMRN: 81.10 (-1.84), INVA: 11.35 (-0.21), ALXN: 135.61 (-2.63), SNY: 39.41 (-1.45)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ortho Molecular and HANS: Streamlining Functional Medicine

Functional Medicine Gets a Tech Boost The world of functional medicine just got a major shot in the arm, courtesy of an intriguing alliance between Ortho Molecular Products and HANS.FM. First of all, let's address the elephant in the room: clinicians in this field aren't exactly on a coffee break. They’re buried under mountains of paperwork, often spending hours just...

CURE Intl and Thoughtworks Step Into Digital Era

Pushing Paper Out, Digitizing In In a world where tech is king, why were hospitals—crucial, life-saving institutions—still bogged down by dusty folders and ink smudges? Well, not anymore for CURE International, not with Thoughtworks stepping up to the plate. This ain't just swapping paper for pixels; it's a lifeline for kids getting world-class surgical care without...

Jinko Solar Joins B20 Summit: Energy Forefront Focus

Jinko Solar's Invitation to the B20 Summit Never a dull moment in the solar space, especially when Jinko Solar, a big shot in clean energy, jumps into the spotlight at the B20 Summit in the U.S. Awash with high-profile discussions, Jinko's not just chatting—it's the only photovoltaic firm strutting its stuff in D.C. with gutsy calls for energy reform. Key Takeaways from...

Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Agilyx's Q3 Update: GreenDot Shines Amid Mixed Results

Peeking into Agilyx's Financial Odyssey Just as I sip my morning coffee pondering the highs and lows of the market, here comes Agilyx ASA splashing some liquidity on the scene. The Q3 report paints the company in various shades—from solid greens to hesitant reds. Nothing like the thrill of untangling mixed results over a quiet day, huh? GreenDot's Climb to Profitability...

Inflatable Wonders Turn Christmas into a Hoot at Lowe's

Inflatables Bringing the Cheer (and Laughs) Well, it's that season again—where decorations either have us grumbling at the electric bill or chuckling at the lawn art. Lowe's has teamed up with Gemmy to serve a heaping platter of holiday giggles this year. They've rolled out a quirky lineup of inflatables that go from shivering Highland cows to dinosaurs and elves....

LG Innotek Scores Hat Trick with CES Innovation Wins

LG Innotek's Lighting Triumph Here we go again, LG Innotek just snagged their third CES Innovation Award in a row, this time for their cutting-edge vehicle lighting module, Nexlide C+. It's one for the books—breaking into the 2027 CES spotlight with innovative tech that not only grabs the eyes but could also steal the hearts of investors willing to bet on the future of...

RF MEDICAL Expands into Europe with New CE Certification

RF MEDICAL Secures CE Marking for Mi-BLATOR™ Just when you think the European medical device market's hit its saturation point, RF MEDICAL decides to kick the door open with their Mi-BLATOR™ microwave ablation system. This ain't just another plastic gadget, folks; it's got that shiny new CE marking under the European Union's Medical Device Regulation (MDR). Now, what...

BD Sets Stage for Investor Day in December 2026

BD's Investor Day: A Peek into the Future Say what you will about investor meets, but BD (Becton, Dickinson and Company) throwing its shindig on December 10, 2026, could be a highlight on the calendar if you're eyeing the medical technology sector. Scheduled in New York, this event is gearing up to be a canvas for BD's higher-ups to sketch out their roadmap. If you’re...

Centrus Energy Welcomes Nuclear Veteran to Leadership

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...